Stopping GLP-1: maintaining satiety without pharmacology
Share
GLP-1 discontinuation: how to maintain satiety regulation without pharmacology?
When treatment stops, appetite returns. But one physiological pathway remains available to support the transition — the mechanical pathway of satiety.
GLP-1 receptor agonists — semaglutide (Ozempic®, Wegovy®), liraglutide (Saxenda®), tirzepatide (Mounjaro®) — represent one of the most significant advances in the management of overweight and obesity. Their efficacy on weight reduction is well documented, with weight losses of 15 to 20% in clinical trials.
But a clinical reality is progressively emerging: many patients discontinue their treatment. Recent data suggest that approximately half of patients stop within the first year. And when treatment stops, appetite returns — often rapidly.
This article explores the mechanisms behind this regain, the reasons for discontinuation, and an emerging question: are there non-pharmacological physiological pathways capable of supporting the transition?
What does the data tell us about weight regain after GLP-1 discontinuation?
The effect of GLP-1 treatments is suspensive: it depends on the continuous administration of the medication. When treatment is interrupted, the underlying physiological mechanisms of appetite reassert themselves — hunger returns, portions increase, and weight regain follows.
Why do patients discontinue their GLP-1 treatment?
GLP-1 discontinuation is rarely an isolated choice. It most often results from a combination of factors that healthcare professionals know well.
Until 15 June 2026, GLP-1s were not reimbursed in France for the obesity indication. Since that date, Wegovy® and Mounjaro® are reimbursed under restricted conditions (BMI ≥ 40, or ≥ 35 with comorbidity). For patients outside these criteria — including the entire BMI 27-35 range — the monthly cost (around €300) remains entirely at the patient's expense. The treatment works — but it is not accessible to everyone, nor indefinitely.
Nausea, vomiting, diarrhoea — gastrointestinal side effects can limit adherence or prevent reaching therapeutic doses. Some patients simply cannot tolerate the treatment, despite its theoretical efficacy.
Some care pathways include a limited treatment duration. The prescriber may decide on progressive tapering or discontinuation after the weight target is achieved. The question becomes: how to maintain the gains without the medication?
Supply shortages of semaglutide and tirzepatide have affected many patients, creating involuntary treatment interruptions. Even temporary, discontinuation is enough to reactivate appetite mechanisms.
These factors in no way diminish the value of GLP-1 therapies. They highlight a concrete clinical need: preparing and supporting the transition when pharmacological treatment ends.
What happens in the body when treatment stops?
GLP-1 receptor agonists produce a sustained pharmacological suppression of the appetite system. They act on four simultaneous levers: slowing gastric emptying, central suppression of hunger, modulation of reward circuits, and sensitisation of vagal afferents.
When the medication is withdrawn, all four effects cease. The system returns to its prior state — often within a few weeks. Hunger returns to pre-treatment intensity, portions increase, snacking resumes.
But a crucial point is often overlooked: not all satiety pathways disappear when treatment stops.
The hormonal pathway shuts down — the mechanical pathway persists
Appetite regulation relies on the integration of two main categories of signals by the brainstem: hormonal signals (GLP-1, CCK, PYY, ghrelin) and mechanical signals (gastric distension, abdominal wall stretch, proprioceptive feedback).
Hormonal signals depend on the continuous administration of a medication. They cease with it. Mechanical signals, however, are endogenous and immediate — they are generated at every meal, every time the stomach fills, independently of any pharmacological treatment.
Mechanical satiety: an under-explored regulatory pathway?
The mechanical component of satiety has been documented through more than seven decades of research. Paintal's foundational work (1954) identified gastric stretch receptors. Phillips and Powley (1998) demonstrated that the vagus nerve is the critical pathway for gastric volume detection. Bai et al. (2019) confirmed at the cellular level that activation of stomach mechanoreceptors powerfully inhibits food intake.
A particularly relevant finding in our context: Geliebter, Westreich and Gage (1986) demonstrated that applying external pressure to the abdomen significantly alters food intake — reducing volume consumed and slowing gastric emptying. This foundational observation suggests that the conditions in which mechanical satiety signals are perceived can be modulated from outside the body.
This opens a clinical perspective: if the mechanical pathway can be supported after GLP-1 discontinuation, it could help maintain part of the appetite regulation acquired during treatment.
Go deeper: What is satiety? Full physiologyHow to support the transition after GLP-1 discontinuation?
Weight regain after GLP-1 discontinuation is not inevitable if the transition is anticipated and structured. Healthcare professionals identify several complementary levers to support patients through this critical phase.
The behavioural and nutritional foundation
Structured dietary follow-up, behavioural support, and adapted physical activity remain the cornerstones of any weight maintenance strategy. These interventions should ideally be in place during GLP-1 treatment, not only after — so that habits are consolidated before discontinuation.
Progressive tapering
Rather than abrupt discontinuation, a progressive dose reduction allows the patient to gradually adapt to the return of appetite signals. This approach provides time to reinforce behavioural strategies and introduce complementary tools.
Mechanical satiety support
It is in this context that the exploration of the mechanical pathway makes sense. A device applying controlled external abdominal compression to the epigastric region could support the perception of mechanical satiety signals — maintaining a physical and sensory reference point during the transition phase, without interfering with hormonal pathways or generating drug interactions.
Why a multi-pathway strategy for appetite regulation?
The rapid adoption of GLP-1s has demonstrated both the potential and the limitations of approaches relying on a single physiological pathway. A paradigm is emerging: sustainable appetite management will likely benefit from the combination of multiple levers.
This logic is not new in medicine. Hypertension management routinely combines medications acting on different pathways. Cancer treatment integrates surgery, chemotherapy, and immunotherapy. The same approach — addressing a complex biological system through complementary mechanisms — applies naturally to appetite regulation.
For patients who discontinue GLP-1 treatment, this perspective offers a concrete framework: the transition is not an abandonment of treatment, but a shift from a single-pathway strategy to a multi-pathway strategy — where nutritional follow-up, behavioural support, and mechanical satiety support work in concert.
Frequently asked questions: GLP-1 discontinuation and appetite
Why do people regain weight after stopping GLP-1?
The effect of GLP-1 treatments is suspensive: it depends on the continuous administration of the medication. Upon discontinuation, the hormonal satiety signals decrease, hunger returns to pre-treatment intensity, and portions increase. Published studies show that on average, two-thirds of weight lost is regained within the year following discontinuation.
Does hunger always return after stopping?
The response varies between individuals. Observational data show that approximately 55% of patients regain weight after stopping, while 45% maintain or continue their loss. Trajectories depend on dietary habits consolidated during treatment, nutritional follow-up, and the duration of medication use.
Can you regulate your appetite without pharmacology after GLP-1?
Appetite regulation relies on multiple physiological pathways — hormonal, behavioural, and mechanical. When the hormonal pathway is withdrawn, the others remain available. Structured dietary follow-up, behavioural support, and support for the mechanical component of satiety can help maintain the regulation acquired during treatment.
Are GLP-1 therapies sufficient long-term?
They represent a major therapeutic advance, but their suspensive effect highlights the need for more comprehensive management. Experts increasingly recognise that sustainable appetite management benefits from multi-pathway approaches combining several physiological levers.
What is the role of mechanical signals in satiety?
Gastric distension and abdominal pressure generate signals transmitted to the brain via the vagus nerve. These mechanical signals are among the earliest determinants of meal termination. Unlike hormonal signals, they are endogenous and immediate — they persist independently of any pharmacological treatment.
Explore mechanical satiety support
Clinical documentation, mechanism of action, and exploratory data available for healthcare professionals.
Information for prescribersGASTER control® — GASTER Technology Limited, 5/1 Merchants Street, Valletta VLT 1171, Malta. Proprietary biomechanical design (patent pending).